echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Jiangsu Province: 133 drugs from 123 pharmaceutical companies have been suspended

    Jiangsu Province: 133 drugs from 123 pharmaceutical companies have been suspended

    • Last Update: 2019-07-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On July 12, Jiangsu public resources trading center issued the notice on suspending the purchase of drugs that failed to pass the quality and efficacy consistency evaluation of generic drugs This is the second time that Jiangsu Province has officially issued a notice to suspend the purchase of non conformance drugs According to the notice, 133 drugs have been suspended from purchasing, involving 123 pharmaceutical companies, including Amoxicillin Capsules, atorvastatin tablets, guanidine hydrochloride tablets and other over evaluated enterprises with 3 varieties The original text of the notice is as follows:
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.